JP, I agree that bonus should be given based on performance and thus far nothing has happened and bonus is based on certain milestones completed. The real problem related to dilution however is working capital expenses and that needs to stop first. Going forward as they will have to manage more products and there will be higher woring capital expenses and need to dilute more if no revenues in place.I'm anxiously waiting on Lympro news and RUO revenues. Once that kicks in it should slow down.